2,3,4,5,6,6-六氯-2,4-环己二烯-1-酮 | 21306-21-8

• 物质功能分类: 有机原料 - 酮类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2,3,4,5,6,6-六氯-2,4-环己二烯-1-酮
• 英文名称: 2,2,3,4,5,6-hexachloro-cyclohexa-2,4-dien-1-one
• 英文别名: 2,3,4,5,6,6-hexachloro-2,4,cyclohexadien-1-one；2,3,4,5,6,6-Hexachloro-2,4-cyclohexadien-1-one；2,3,4,5,6,6-hexachlorocyclohexa-2,4-dien-1-one
• CAS: 21306-21-8
• 化学式: C₆Cl₆O
• mdl: MFCD00019431
• 分子量: 300.783
• InChiKey: BBLJNWQYENOWPH-UHFFFAOYSA-N

物化性质

• 熔点：
  46-49 °C
• 沸点：
  110-112 °C(Press: 0.1 Torr)
• 密度：
  1.7737 (estimate)
• 稳定性/保质期：
  遵照规定使用和储存，则不会发生分解。

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2914700090
• 安全说明：
  S24/25
• 储存条件：
  存储于阴凉干燥处。

SDS

Name:	2 3 4 5 6 6-Hexachloro-2 4-Cyclohexadien-1-One 99% Material Safety Data Sheet
Synonym:
CAS:	21306-21-8

Section 1 - Chemical Product MSDS Name:2 3 4 5 6 6-Hexachloro-2 4-Cyclohexadien-1-One 99% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
21306-21-8	2,3,4,5,6,6-Hexachloro-2,4-Cyclohexadi	99	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation. The toxicological properties of this material have not been fully investigated.
Skin:
May cause skin irritation. The toxicological properties of this material have not been fully investigated.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Never give anything by mouth to an unconscious person. Get medical aid immediately.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 21306-21-8: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystals
Color: yellow to brown
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 46.00 - 49.00 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6Cl6O
Molecular Weight: 300.77

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Irritating and toxic fumes and gases.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 21306-21-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2,3,4,5,6,6-Hexachloro-2,4-Cyclohexadien-1 -One - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 21306-21-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 21306-21-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 21306-21-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,3,4,5,6,6-六氯-2,4-环己二烯-1-酮 在 O-benzoylquinine 作用下， 以 四氢呋喃 为溶剂， 反应 3.5h， 生成 (S)-N-benzyl-2-chloro-2-phenylacetamide
  参考文献：
  名称：

  酰卤的催化不对称 α-氯化

  摘要：

  我们全面介绍了串联催化、不对称氯化/酯化过程，该过程使用金鸡纳生物碱衍生物作为催化剂和多氯醌作为卤化剂，从廉价的市售酰卤中生产高度光学富集的 α-氯酯。我们已经进行了动力学和控制实验，以研究反应机理并建立可以最好地进行反应的条件。我们开发了 NaH 和 NaHCO3 穿梭基系统作为进行反应的最简单和最具成本效益的方法，使该方法与已知的手性卤化程序在经济上具有竞争力。我们还通过将产品转化为合成有用的衍生物来证明我们的反应的效用。

  DOI：

  10.1021/ja039046t
• 作为产物：
  描述：

  五氯酚钠 在 chlore 作用下， 以 四氯化碳 为溶剂， 反应 3.0h， 以56.5%的产率得到2,3,4,5,6,6-六氯-2,4-环己二烯-1-酮
  参考文献：
  名称：

  卤代区域选择性芳香反应-I：酚类和微量醚的氯化反应，反应性表面活性剂与受体之间的相互作用

  摘要：

  描述了一种有效的区域特异性途径，用于氯化涉及六氯环己二酮的苯酚。通过使用以能够参与电荷转移相互作用和与底物的氢键结合的方式定制的试剂来实现选择性。底物（苯酚）和2，3，4，4，5之间的这种识别，6- hexachlorocyclohexa 2,5二烯-1-酮1我们称之为“réactif p ”允许苯酚在氯化对位置。使用2、3、4、5、6、6-六氯环己基2，4-二烯-1（我们称为“ reactif o ”）2可以在邻位进行氯化位置。这两种试剂是稳定且廉价的材料，由五氯苯酚和氯气合成。在空间控制下，用这两种试剂氯化苯甲醚，仅得到对氯衍生物。

  DOI：

  10.1016/0040-4020(82)87011-7
• 作为试剂：
  描述：

  6-(苄氧基)-1-己醇 在 sodium tetrahydroborate 、 2,3,4,5,6,6-六氯-2,4-环己二烯-1-酮 、 (2R,5S)-2-(tert-butyl)-3,5-dimethylimidazolidin-4-one trifluoroacetate 、 pyridinium chlorochromate 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 为溶剂， 反应 0.58h， 生成
  参考文献：
  名称：

  饱和羟基脂肪酸和羟基脂肪酸脂肪酸酯的不对称合成

  摘要：

  基于手性环氧化物的有机催化合成，开发了生物活性羟基脂肪酸和羟基脂肪酸脂肪酸酯的便捷对映选择性合成方法。

  DOI：

  10.1002/ejoc.201801881

文献信息

• PROCESS OF MAKING SOMATOSTATIN MODULATORS
  申请人：Crinetics Pharmaceuticals, Inc.

  公开号：US20190218202A1

  公开（公告）日：2019-07-18

  Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.

  本文描述了一些肽类抑制素调节剂化合物，制备这类化合物的方法，包含这类化合物的药物组合物和药物，以及利用这类化合物治疗需要调节肽类抑制素活性的疾病、症状或疾病的方法。
• Non-steroidal, tetracylic compounds for estrogen-related treatments
  申请人：——

  公开号：US20030144313A1

  公开（公告）日：2003-07-31

  The invention provides non-steroidal estrogenic compounds with estrogenic and anti-estrogenic compounds effects for treatment of estrogen-deficiency related disorders, which compounds are having formula (I) wherein, one of R a or R b is 'R e ; R e and 'R e are OH, optionally independently etherified or esterified; X is N or —C(R 1 )—, wherein R 1 is H, halogen, CN, optionally substituted aryl, (1C-4C)alkyl, (2C-4C)alkenyl, (2C-4C)alkynyl or (3C-6C)cycloalkyl, which alkyl, alkenyl, alkynyl and cycloalkyl groups can optionally be substituted with one or more halogens; Y is N or —C(R 2 )—, with the proviso that X and Y are not both N, wherein R 2 has the same meaning as defined for R 1 ; Z is C(R 3 ,'R 3 )— or —C(R 4 ,'R 4 )—C(R 5 ,'R 5 )—, wherein R 3 , 'R 3 , R 4 , 'R 4 , R 5 , and 'R 5 , independently arc H, (1C-4C)alkyl, (2C-4C)alkenyl or (3C-6C) cycloalkyl, which alkyl, alkenyl and cycloalkyl groups can optionally be substituted with one or more halogens. These compounds are useful for estrogen-receptor related treatments in view of a desirable profile of activity for estrogen &agr; and estrogen &bgr; receptors.

  该发明提供了一种非甾体雌激素化合物，具有雌激素和抗雌激素作用，用于治疗与雌激素缺乏相关的疾病，这些化合物具有以下结构式（I），其中，R a 或R b 中的一个是'R e ；R e 和'R e 分别是OH，可以独立地醚化或酯化；X是N或—C(R 1 )—，其中R 1 是H，卤素，CN，可选择性地取代的芳基，（1C-4C）烷基，（2C-4C）烯基，（2C-4C）炔基或（3C-6C）环烷基，这些烷基，烯基，炔基和环烷基基团可以选择性地被一个或多个卤素取代；Y是N或—C(R 2 )—，但X和Y不能同时为N，其中R 2 具有与R 1 定义相同的含义；Z是C(R 3 ,'R 3 )—或—C(R 4 ,'R 4 )—C(R 5 ,'R 5 )—，其中R 3 ，'R 3 ，R 4 ，'R 4 ，R 5 和'R 5 ，独立地为H，（1C-4C）烷基，（2C-4C）烯基或（3C-6C）环烷基，这些烷基，烯基和环烷基基团可以选择性地被一个或多个卤素取代。这些化合物在雌激素受体相关治疗中具有用处，因为它们对雌激素α和雌激素β受体具有理想的活性特性。
• [EN] CATALYTIC ASYMMETRIC SYNTHESIS OF OPTICALLY ACTIVE alpha-HALO-CARBONYL COMPOUNDS<br/>[FR] SYNTHESE ASYMETRIQUE CATALYTIQUE DE COMPOSES DE DOLLAR G(A)-HALO-CARBONYLE OPTIQUEMENT ACTIFS
  申请人：HALLAND NIS

  公开号：WO2005080298A1

  公开（公告）日：2005-09-01

  A process for the catalytic asymmetric synthesis of an optically active compound of the formula (la) or (lb): wherein R is an organic group; X is halogen; Rl and R2which may the same or different represents H, or an organic group or Rl and R2 may be bridged together forming part of a ring system; R and R2 may be bridged together forming part of a ring system; with the provisio that R and Rl are different and R2, when different from H, is attached though a carbon-carbon bond, comprising the step of reacting a compound of the formula (2): with a halogenation agent in the presence of a catalytic amount of a chiral nitrogen containing organic compound.

  一种用于催化不对称合成光学活性化合物的方法，其化学式为(la)或(lb)：其中R是有机基团；X是卤素；R1和R2可以相同也可以不同，分别代表H，或者是有机基团，或者R1和R2可以通过形成环系统的桥连接在一起；R和R2可以通过形成环系统的桥连接在一起；在R和R1不同且R2与H不同时通过碳-碳键连接时，包括以下步骤：将化合物(2)与卤化试剂在含有含有手性氮的有机化合物的催化剂量的情况下反应。
• Harnessing Redox-Active Ligands for Low-Barrier Radical Addition at Oxorhenium Complexes
  作者：Cameron A. Lippert、Kenneth I. Hardcastle、Jake D. Soper

  DOI：10.1021/ic200923q

  日期：2011.10.17

  oxorhenium(V) anion [ReV(O)(apPh)2]− [apPh]2– = 2,4-di-tert-butyl-6-(phenylamido)phenolate} gives new products containing Re–X bonds. The Re–X bond-forming reaction is analogous to oxo transfer to [ReV(O)(apPh)2]− in that both are 2e– redox processes, but the electronic structures of the products are different. Whereas oxo addition to [ReV(O)(apPh)2]− yields a closed-shell [ReVII(O)2(apPh)2]− product

  [X] +亲电子试剂加到五配位氧or（V）阴离子[Re V（O）（ap Ph）2 ] - [ap Ph ] 2– = 2,4-二叔丁基- 6-（苯基氨基）酚盐}产生了包含Re–X键的新产品。了Re-X键形成反应是类似于氧转移至[重新V（O）（AP博士）2 ] -在这两者都是2E -氧化还原过程，但产品的电子结构是不同的。而[Re V（O）（ap Ph）2 ]的羰基合成-产率的封闭壳[再VII（O）2（AP博士）2 ] - 2e的产物-金属氧化，[CL] +加成给出一个双价基团重新VI（O）（AP博士）（ISQ博士）氯产物（ [ISQ博士] • - = 2,4-二-叔丁基-6-（苯基亚氨基）semiquinonate）与1E -在重新d轨道和1E -上的氧化还原活性的配体。电子结构的差异归因于[O] 2–和Cl –的π碱度的差异。配体。Re VI（O）（ap Ph）（isq Ph）X中配体自由基的观察为氧化还原活性配体在[Re
• [EN] PROCESSES FOR THE STEREOSELECTIVE PREPARATION OF P-CHIRAL FOUR -COORDINATED PHOSPHORUS BORANE COMPOUNDS AND P-CHIRAL THREE-COORDINATED PHOSPHORUS COMPOUNDS<br/>[FR] PROCÉDÉS POUR LA PRÉPARATION STÉRÉOSÉLECTIVE DE COMPOSÉS DE BORANE DE PHOSPHORE À QUATRE COORDINATIONS P-CHIRAUX ET DE COMPOSÉS PHOSPHORÉS À TROIS COORDINATIONS P CHIRAUX
  申请人：UNIV DUBLIN

  公开号：WO2012113889A1

  公开（公告）日：2012-08-30

  Processes for the stereoselective preparation of P-chiral four-coordinated phosphorus borane compounds and P-chiral three-coordinated phosphorus compounds.

  P-手性四配位磷硼烷化合物和P-手性三配位磷化合物的立体选择性制备过程。